Why the United States Precision Medicine Market Is Growing With the Shift Toward Individualized Care

Personalized medicine is a shift away from the 'one size fits all' approach to medicine‚ to using genetic information‚ biomarkers‚ data and digital health tools to provide the information needed to understand the best way to tailor healthcare for a given person․ This is driving the precision medicine market in the United States (US)‚ where precision medicine refers to medicine that matches treatment as closely as possible to the individual characteristics of each patient․ In 2024‚ IMARC Group projected that United States precision medicine market would be USD 38․4 billion‚ by 2033 it will be USD 43․2 billion‚ at a CAGR of 11․7% from 2025 to 2033․

Increasing prevalence of chronic disease is a major growth driver for the market․ According to IMARC‚ the driving factors for the precision medicine market include increasing prevalence of diseases such as cancer and cardiovascular disease‚ growing volume of healthcare data‚ advances in genomic research‚ and growing usage of artificial intelligence and machine learning․ The report also identifies government support‚ personalized medicine‚ and collaboration of healthcare and technology companies as additional factors driving the market․

An emerging trend in the market is the growing use of pharmacogenomics‚ which refers to the study of how genes affect a person's response to drugs․ In the U․S․ market‚ IMARC projects there will be increasing use of pharmacogenomics in drug development and healthcare․ For example‚ in June 2024‚ they partnered with PGxAI to build an AI model to create pharmacogenomics recommendations to better characterize how patients respond to medications․ The company considers this a landmark accomplishment for precision medicine‚ as it applies to clinical practice rather than research settings․

Another trend includes the increasing usage of next-generation sequencing (NGS)․ IMARC identifies the faster and cheaper nature of the NGS techniques compared to customary methods of genetic profiling as a driver of this trend․ The report cites Illumina's MiSeq i100 Series‚ and its launch in October 2024‚ as an example of how sequencing tools are advancing laboratory capabilities․ NGS is increasingly being utilized to identify biomarkers‚ detect rare mutations and implement more personalized treatment regimens with respect to oncology‚ among other indications and applications․

The role of artificial intelligence (AI) is also growing․ IMARC states that increased use of AI and digital health technologies is a market driver as institutions use AI to process data‚ predict disease risk‚ and target treatment for certain groups of patients․ Citing HIMSS Market Insights research‚ reported in October 2024‚ that more than 60% of healthcare organizations planned to implement AI-based technologies such as generative AI‚ predictive analytics and workflow automation within three years‚ the report concludes that precision medicine is increasingly intertwined with the digitalization of healthcare‚ rather than being developed in isolation․

What makes this market particularly interesting is the fact that the market is expanding from so many sides at once․ It's not just better diagnostics․ This includes adopting connected approaches to diagnostics‚ drug development‚ clinical decision making‚ patient monitoring and long-term preventative care․ The IMARC states that with direct-to-consumer genetic testing increasing in availability‚ patients are becoming more familiar with and involved in genetic testing․ The collaboration between research centers and networks reveals how scientific advances are entering the standard clinical algorithm‚ suggesting a market in which patient participation and institutional innovation are becoming more important․

According to the IMARC‚ the market is segmented by product into consumables‚ instruments‚ and services․ The market is divided by technology into big data analytics‚ bioinformatics‚ gene sequencing‚ drug discovery‚ companion diagnostics‚ and others․ By application‚ the market is segmented into oncology‚ central nervous system (CNS)‚ immunology‚ respiratory medicine‚ infections‚ and others․ By end user‚ the market is segmented into hospitals and clinics‚ diagnostic centers‚ pharma and biotech‚ healthcare IT‚ and others․ That structure shows how broad the opportunity has become: precision medicine is no longer a specialty field‚ but a growing ecosystem of research‚ diagnostics‚ treatment‚ and digital health․

Oncology is one of the most prominent applications․ According to IMARC‚ in the United States‚ the demand for precision medicine in oncology is driven by novel advancements in genomic profiling‚ as well as the advent of targeted therapies that are tailored to patients' and tumors' profiles․ That matters because oncology is in many ways the most developed field of precision medicine: the better we match treatment with biology‚ the better the outcome and the fewer the side effects․

What makes the United States precision medicine market most important‚ however‚ is that it is representative of a broader shift in the way healthcare in general is being understood․ Medical professionals are moving away from general population treatment toward the goal of understanding what makes each patient tick from a genomic and clinical perspective․ Given the aforementioned growth drivers‚ trends‚ and segmentation‚ genomics‚ bioinformatics‚ artificial intelligence‚ and sequencing technologies are expected to lead to further integration of precision medicine into routine practise in the future‚ according to IMARC․

For readers who want a closer look at forecast data, technology trends, and application segments, the full IMARC Group study offers more detailed insight.